| Literature DB >> 16981178 |
Florian Obermeier1, Martin Hausmann, Silvia Kellermeier, Stefan Kiessling, Ulrike G Strauch, Erwin Duitman, Silvia Bulfone-Paus, Hans Herfarth, Jürgen Bock, Nadja Dunger, Michael Stoeck, Jürgen Schölmerich, Werner Falk, Gerhard Rogler.
Abstract
IL-15, a T-cell growth factor, has been shown to be increased in inflammatory bowel disease (IBD). It has been suggested that neutralization of IL-15 could protect from T cell-dependent autoimmune inflammation. On the other hand, an anti-apoptotic effect of IL-15 has been demonstrated in kidney epithelial cells during nephritis. We therefore tested the role of IL-15 in two different experimental models of colitis in vivo, and in models of intestinal epithelial cell (IEC) apoptosis in vitro. IL-15 blockade in chronic dextran sulphate sodium-induced colitis resulted in aggravation of the disease with a significantly 2.1-fold increased epithelial damage score compared to controls. TUNEL staining clearly revealed increased apoptosis. IL-6, TNF and IFN-gamma secretion by mesenteric lymph node cells were increased. In the T cell-dependent SCID transfer model of colitis IL-15 neutralization reduced the inflammatory infiltration and proinflammatory cytokine production. Despite that, the intestinal epithelial damage was not reduced. In vitro, IL-15 pre-incubation prevented up to 75% of CH11 antibody-induced apoptosis in SW-480 cells and reduced caspase-3 activity. According to this, endogenously produced IL-15 in chronic colitis does not only act as a proinflammatory cytokine but has at the same time the potential to reduce mucosal damage by preventing IEC apoptosis.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16981178 DOI: 10.1002/eji.200535173
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532